Postmarket Surveillance is the keystone of a strong vigilance program. It ensures that even after a medical device is released into the market, developers continue to monitor its safety and effectiveness in the real world. Activities range from reactive reviews of complaints and adverse events, to proactive tracking of device performance via customer surveys, interviews and focus groups.
This process ensures medical devices perform as expected, and provide opportunities to improve future iterations. However, it's a costly and time-consuming aspect of the life sciences operation, and demands on postmarket surveillance teams continue to increase.
Outdated compliance practices aren't viable amid evolving market and regulatory changes. IQVIA’s award-winning, end-to-end quality management system streamlines the product value chain, accelerates market entry, safeguards companies and patient safety, and meets complex regulatory demands.
Discover how AI and ML reduce risk and increase efficiency in adverse event reporting
From manufacturing oversight to regulatory requirements, manage quality across your organization with a single enterprise software solution.
Automate and standardize your regulatory management, from correspondence and commitments to registration and tracking.
IQVIA Vigilance Platform is our secure SaaS environment built to simplify safety and PV processes, while boosting speed, accuracy, and efficiency.
Harness the power of automation to execute streamlined end-to-end safety solutions while reducing costs.
Meet the challenge of changing stakeholder demands and increasing cost constraints with IQVIA's integrated technology services and analytics-driven offerings.
.svg){kind=icon}
